PBHXNYSAS OF Nov 10, 2026

Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. (PBH) is a $2.0B company listed on XNYS, trading at $44.97. It scores 6/6 on Tickr's valuation checks, trading 35% below its $68.75 DCF fair value. Its P/E of 13.9× compares to a 14.0× peer-group median. 5 analysts carry a mean price target of $66.60 (+32.5%). Tickr's AI funds have no public trades in PBH.

PRICE

$44.97

FAIR VALUE

$68.75

BELOW FAIR VALUE

−35%

ANALYST TARGET

$66.60

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

THE AI DESK ON PBH

Tickr's three AI funds have no public trades in PBH. Their live books — every position and the reasoning behind it — are on the AI Funds page.

VALUATION

6/6 CHECKS PASSED

✓BELOW FAIR VALUETrades under its DCF fair value.
✓SIGNIFICANTLY BELOWMore than 20% under fair value.
✓CHEAP VS PEERSMultiple below the peer-group median.
✓CHEAP VS INDUSTRYMultiple below the industry median.
✓CHEAP VS OWN HISTORYMultiple below its own 5-year median.
✓BELOW FAIR MULTIPLEMultiple below the growth-justified fair multiple.

PBH P/E

13.9×

PEER MEDIAN

14.0×

INDUSTRY MEDIAN

20.4×

OWN 5YR MEDIAN

16.2×

PEER GROUP · XLV:pharma

SYMBOL	P/E	MKT CAP	GROWTH
AUPH	7.1×	$2.2B	19.6%
PBH	13.9×	$2.1B	13.0%
HRMY	11.1×	$2.0B	34.1%
ETON	43.9×	$1.9B	47.1%
SRPT	821.0×	$1.8B	-45.9%
NRIX	6.5×	$1.7B	-142.2%
PGEN	41.1×	$1.6B	—
ANIP	14.2×	$1.6B	9.3%

PRICE ACTION

NO PRICE DATA

DAILY CLOSES

FUNDAMENTALS

10-Q · PERIOD ENDED Jun 30, 2026

PROFIT MARGIN

11.0%

OPERATING MARGIN

19.8%

RETURN ON EQUITY

1.5%

DEBT / EQUITY

1.05

DILUTED EPS

$0.61

ASSETS / LIABILITIES

1.72

ASSET TURNOVER

0.06

LEVERAGE

2.38

ANALYST CONSENSUS

AS OF Nov 10, 2026

MEAN TARGET

$66.60

IMPLIED UPSIDE

+32.5%

COVERING FIRMS

UP / DOWN (30D)

0 / 0

THREE AI FUNDS. EVERY TRADE EXPLAINED.

The valuation work on this page is the same data three language-model PMs read before they trade. Follow all three books live — every position the day it's taken, with the reasoning — on the AI Funds page.

FOLLOW THE BOOKS LIVE →

⚠ Not investment advice. Fair value, valuation checks and peer groups are model estimates from automated pipelines and can be wrong or stale; fundamentals are drawn from the company's most recent SEC filing. Nothing here is a recommendation to buy or sell any security. Full disclaimer · How the desk works.